FAVIPIRAVIR

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
ATC J05AX27
UNII EW5GL2X7E0

Structure

InChI Key ZCGNOVWYSGBHAU-UHFFFAOYSA-N
Smiles NC(=O)c1nc(F)cnc1O
InChI
InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11)

Physicochemical Descriptors

Property Name Value
Molecular Formula C5H4FN3O2
Molecular Weight 157.1
AlogP -0.58
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 1.0
Polar Surface Area 89.1
Molecular species NEUTRAL
Aromatic Rings 1.0
Heavy Atoms 11.0

Bioactivity

Mechanism of Action Action Reference
RNA-directed RNA polymerase inhibitor INHIBITOR PMDA PubMed
Assay Description Organism Bioactivity Reference
Antiviral activity against influenza B virus Influenza B virus 89.0 nM
Antiviral activity against Influenza C virus Influenza C virus 44.0 nM
Antiviral activity against influenza H1N1 virus Influenza A virus 160.0 nM
Antiviral activity against influenza H2N2 virus H2N2 subtype 48.0 nM
Antiviral activity against influenza A virus Influenza A virus 83.0 nM
Antiviral activity against adamantane-susceptible zanamivir-, oseltamivir-resistant Influenza A virus (A/Brazil/1633/2008(H1N1)) harboring neuraminidase Q136K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Influenza A virus 830.0 nM
Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/New York/34/2008(H1N1)) harboring M2 L26I mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Influenza A virus 190.0 nM
Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Influenza A virus (A/Florida/01/2009(H3N2)) 450.0 nM
Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Influenza B virus (B/Memphis/20/96) 570.0 nM
Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Swine/South Dakota/03/2008(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Influenza A virus 830.0 nM
Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/California/05/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Influenza A virus (A/California/05/2009(H1N1)) 830.0 nM
Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/pdm/New York/18/2009 (H1N1)) harboring M2 V28I, S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Influenza A virus (A/New York/18/2009(H1N1)) 890.0 nM
Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Ann Arbor/6/1960(H2N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Influenza A virus (A/Ann Arbor/6/1960(H2N2)) 380.0 nM
Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) 960.0 nM
Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain Influenza A virus (A/turkey/Minnesota/833/1980(H4N2)) 890.0 nM
Antiviral activity against Respiratory syncytial virus A2 infected in Hep2 cells Human respiratory syncytial virus A2 41.0 ug.mL-1
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 38.35 %
Antiviral activity against Ebolavirus infected in African green monkey Vero cells by immunofluorescent assay Ebolavirus 18.6 ug.mL-1
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 85.77 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.01 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.01 %

Cross References

Resources Reference
ChEBI 134722
ChEMBL CHEMBL221722
DrugBank DB12466
DrugCentral 4887
FDA SRS EW5GL2X7E0
Guide to Pharmacology 11139
PubChem 492405
SureChEMBL SCHEMBL587913
ZINC ZINC000013915654
CONTENTS